@jon-nyc said in GLP-1 agonists to be among 15 drugs subject to Medicare price negotiations:
Me: What’s the next generation of weight loss drugs after GLP-1 agonists.
ChstGPT:
Multi-Receptor Agonists:
• Dual and Triple Agonists: Pharmaceutical companies are developing drugs that target multiple receptors to enhance weight loss efficacy. For instance, Eli Lilly’s retatrutide is a “triple G” agonist that activates GLP-1, GIP, and glucagon receptors. In mid-stage trials, participants achieved up to 24.2% weight loss over 48 weeks, marking significant progress in obesity treatment. 
https://x.com/nbcnews/status/1922000128556019934?s=46